Clinical trial
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Women (PROMOTE-PIs)
This study is an open-label, single site, randomized controlled trial comparing protease inhibitor (PI)-based antiretroviral therapy (ART) to non-PI based ART for HIV-infected pregnant and breastfeeding women of all CD4 cell counts at high risk of malaria. The study is designed to test the hypothesis that pregnant women receiving a PI-based ART regimen will have lower risk of placental malaria compared to pregnant women receiving a non-PI based ART regimen. The primary study endpoint of the study is placental malaria.
Category | Value |
---|---|
Study start date | 2009-10-08 |